L- -methyl- -hydrazino- -(3,4-dihydroxyphenyl)propionic acid: relative lack of antidecarboxylase activity in adrenals.
In rats previously treated with a monoamine oxidase inhibitor, the administration of 5-hydroxytryptophan results in increases in concentrations of 5-hydroxytryptamine in kidney, brain, and adrenal glands. When the peripheral L-aromatic amino acid decarboxylase inhibitor, L-alpha-methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenyl)propionic acid (HMD) is administered prior to 5-hydroxytryptophan, the concentration of 5-hydroxytryptamine in kidneys does not rise, that of the brain increases slightly, and that of the adrenal rises markedly. This indicates that although the adrenal gland is a peripheral organ, it does not respond in the typical manner to the antidecarboxylase action of HMD. These results suggest that HMD does not gain free access into the adrenal medulla and that a possible "blood-adrenal barrier" may exist to this compound.
D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000311:Adrenal Glands / Q000032:analysis / Q000201:enzymology*; D000818:Animals; D001923:Brain Chemistry; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors*; D002396:Catechols / Q000494:pharmacology; D005260:Female; D006834:Hydrazines / Q000008:administration & dosage / Q000494:pharmacology; D007668:Kidney / Q000032:analysis; D008750:Methyldopa / Q000008:administration & dosage / Q000494:pharmacology*; D010293:Pargyline / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000032:analysis; D013997:Time Factors
D002396:Catechols; D006834:Hydrazines; D011422:Propionates; D012701:Serotonin; D008750:Methyldopa; D010293:Pargyline; D006916:5-Hydroxytryptophan; D002262:Carboxy-Lyases